KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Pacritinib: First Approval.

Yvette N Lamb

Drugs 82(7) 831-838

PMID35567653
PMCID-
DOI10.1007/s40265-022-01718-y
发表日期2022-05-14
摘要

摘要

Pacritinib (VONJO™) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of myelofibrosis and graft-versus-host disease. Pacritinib received its first approval in February 2022 in the USA for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. The accelerated approval was based on results from the randomized, active-controlled, phase III PERSIST-2 trial, in which spleen volume reduction was demonstrated in pacritinib recipients. This article summarizes the milestones in the development of pacritinib leading to this first approval for myelofibrosis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。